AstraZeneca/Alexion’s danicopan, Biogen’s tofersen, Incyte’s retifanlimab and Vifor/Travere Therapeutics’ sparsentan are four orphan drug candidates that could potentially be backed for pan-EU marketing approval this week.
The four drugs are among 11 new products listed as being up for an opinion on whether they should be...








